Every Form 4 that Clorox Co Del (CLX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLX filings page.
Clorox executive Nina Barton reported a Form 4 reflecting a tax-withholding disposition, where the company withheld 1,681 shares of Common Stock at $95.69 per share to satisfy taxes on vesting of restricted stock. After this, she directly holds 26,443 shares, including 229 acquired via the Stock Incentive Plan’s dividend reinvestment feature. The transaction is not marked as pursuant to a Rule 10b5-1 plan.
Clorox executive Chris T. Hyder, EVP-Chief Operating Officer, reported a tax-related share withholding on 2026-07-15. The company withheld 277 shares of common stock at $94.75 per share to satisfy tax obligations tied to vesting restricted stock, leaving Hyder with 76,860 directly held shares, including 36 acquired through a dividend reinvestment feature.
Clorox director Christopher J. Williams reported two compensation-related awards of deferred stock units. On May 8, 2026, he received 297.0104 deferred stock units, and on June 30, 2026, he received 288.1391 deferred stock units.
The filing explains these units were acquired through dividend reinvestment during the fiscal year and by electing to receive quarterly director fees in deferred stock units under the Independent Directors' Deferred Compensation Plan. Each unit represents a 1-for-1 right to receive Clorox common stock, to be settled in shares after his retirement or other termination of board service. Following the latest award, Williams holds a total of 22,659.7313 deferred stock units directly.
Clorox director Russell J. Weiner reported two compensation-related grants of Deferred Stock Units, increasing his deferred equity-based holdings. He acquired 353.6253 Deferred Stock Units on June 30, 2026 and 242.2414 units on May 8, 2026, both recorded at a price of $0.0000 per unit as non-cash awards.
These units correspond 1-for-1 to shares of Clorox common stock and are linked to the company’s Independent Directors' Deferred Compensation Plan through dividend reinvestment and the election to receive quarterly director fees in Deferred Stock Units. After the June award, Weiner directly holds 18,599.8701 Deferred Stock Units, which will be settled entirely in Clorox stock upon his retirement or other termination of service as a director.
Clorox director Stephanie Plaines reported routine compensation-related awards of deferred stock units, not open-market trades. She acquired 288.1391 deferred stock units on June 30, 2026 and 103.9395 units on May 8, 2026, both at a stated price of $0.
The units were granted under the Independent Directors' Deferred Compensation Plan, including amounts acquired through dividend reinvestment and in lieu of quarterly director fees. After these awards, she held a total of 8,117.1272 deferred stock units, which will be settled entirely in Clorox common stock when she retires from, or otherwise leaves, the board.
Clorox director Pierre R. Breber reported changes in his equity-based compensation and holdings. He indirectly holds 18,000 shares of Clorox common stock through a trust. Separately, he acquired Deferred Stock Units in two transactions: 353.6253 units and 41.7110 units, each representing a right to receive one share of common stock.
The filing notes that these Deferred Stock Units were acquired through dividend reinvestment and in lieu of quarterly director fees under the Independent Directors' Deferred Compensation Plan. The units will be settled entirely in Clorox stock upon his retirement or other termination of service as a director, and he now holds 3,495.4037 Deferred Stock Units directly.
Clorox director Matthew J. Shattock reported two non-cash awards of Deferred Stock Units. He acquired 550.0838 units on June 30, 2026 and 270.7961 units on May 8, 2026, tied to dividend reinvestment and electing fees in stock under the Independent Directors' Deferred Compensation Plan. These units, which track Clorox common stock 1-for-1, will be settled in Clorox shares when he retires or otherwise leaves the board. Following the most recent award, he directly holds 20,947.1472 Deferred Stock Units.
Bellet Luc reported acquisition or exercise transactions in this Form 4 filing.
Clorox Executive Vice President and Chief Financial Officer Luc Bellet received a grant of 42,118 shares in the form of restricted stock units at a reference price of $94.97 per share. These units will vest in full on June 17, 2029, increasing his direct holdings to 62,756 shares.
Hilt Angela C reported acquisition or exercise transactions in this Form 4 filing.
CLOROX CO executive Angela C. Hilt, EVP and Chief Legal Officer, received a grant of 26,324 shares of common stock on June 17, 2026, reported at $94.97 per share as a compensation award. These are in the form of Restricted Stock Units that will vest in full on June 17, 2029.
Following the award, she holds 56,111 common shares directly and 657.357 shares indirectly through a 401(k) plan. This filing reflects an equity compensation grant rather than an open‑market purchase or sale.
Marriner Kirsten reported acquisition or exercise transactions in this Form 4 filing.
Clorox executive Kirsten Marriner received a compensation-related stock grant. On June 17, 2026, the EVP – Chief Admin Officer was awarded 26,324 shares of Clorox common stock at a reference price of $94.97 per share. Following this award, her direct holdings increased to 64,294 shares.
The award is structured as Restricted Stock Units that will vest in three equal installments, with one-third scheduled to vest on each of June 17, 2027, June 17, 2028 and June 17, 2029, aligning incentives over multiple years.
Hyder Chris T reported acquisition or exercise transactions in this Form 4 filing.
Clorox executive Chris T. Hyder received a stock grant that increases his direct holdings. He was awarded 42,118 shares of Clorox common stock on June 17, 2026, as a grant or award valued at $94.97 per share. After this grant, he directly holds 77,087 shares. A related footnote states that these Restricted Stock Units will vest in full on June 17, 2029, three years after the grant date.
Clorox director Pierre R. Breber, through a trust, made an open-market purchase of 5,000 shares of Common Stock at a weighted average price of about $85.82 per share. Following this transaction, the trust’s indirect holdings increased to 18,000 Clorox shares.
The shares were bought in multiple trades within a price range from $85.19 to $86.01, according to the filing footnote.
Clorox Co (CLX) EVP and CFO Luc Bellet reported a routine tax-related share disposition. On vesting of restricted stock, the company withheld 244 shares of common stock at $103.63 per share to cover tax obligations, rather than selling shares in the open market.
After this withholding, Bellet directly holds 20,638 shares of Clorox common stock. Footnotes also note that this total includes 18 shares acquired through a dividend reinvestment feature under the company’s Stock Incentive Plan.
Clorox director Christopher J. Williams reported routine compensation-related awards of Deferred Stock Units. He acquired 265.3672 units on March 31, 2026 and 212.6390 units on February 13, 2026, with each unit representing one share of Clorox common stock.
Some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan and some in lieu of quarterly director fees. These Deferred Stock Units will be settled entirely in Clorox stock when Williams retires or otherwise leaves the board, bringing his reported Deferred Stock Unit balance to 22,074.5818 units held directly.
Clorox (CLX) director Russell J. Weiner reported routine compensation-related acquisitions of Deferred Stock Units. On February 13, 2026, he received 172.3630 Deferred Stock Units, and on March 31, 2026, he received 325.6779 Deferred Stock Units, each on a 1-for-1 basis linked to Clorox common stock.
According to the footnotes, some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan and others in lieu of quarterly director fees. The units will be settled entirely in Clorox stock upon his retirement or other termination of service as a director. Following these awards, his reported balance is 18,004.0034 Deferred Stock Units held directly.
Clorox director Pierre R. Breber reported routine compensation-related awards of Deferred Stock Units tied 1-for-1 to Clorox common stock. On March 31, 2026, he acquired 325.6779 Deferred Stock Units, bringing his holdings to 3100.0674 units. On February 13, 2026, he had received an additional 27.0502 units.
According to the disclosures, some Deferred Stock Units were acquired through dividend reinvestment during the fiscal year under the Independent Directors' Deferred Compensation Plan and some were received in lieu of quarterly director fees. These units will be settled entirely in Clorox stock when Breber retires or otherwise leaves the board, and do not reflect open-market buying or selling.
Clorox director Matthew J. Shattock reported routine equity-based compensation in the form of deferred stock units. He acquired 506.6101 deferred stock units on March 31, 2026 and 191.2909 units on February 13, 2026, each on a 1-for-1 basis with Clorox common stock.
The units were received through dividend reinvestment and in lieu of quarterly director fees under the Independent Directors' Deferred Compensation Plan and will be settled in Clorox stock after his retirement or other termination of board service. Following these awards, he directly holds 20,126.2673 deferred stock units.
Clorox director Stephanie Plaines reported awards of deferred stock units that increase her equity-based compensation stake. She acquired 265.3672 deferred stock units on March 31, 2026 and 72.7316 units on February 13, 2026, both at a stated price of $0.00 per unit as non-cash awards.
The units are credited 1-for-1 in relation to Clorox common stock and arise from dividend reinvestment during the fiscal year and receipt of deferred units instead of quarterly director fees under the Independent Directors' Deferred Compensation Plan. Following the latest award, she holds a total of 7,725.0486 deferred stock units, which will be settled entirely in Clorox stock upon her retirement or other termination of board service.
Clorox executive Chris T. Hyder reported a small tax-related share disposition. On the vesting of restricted stock, 41 shares of Clorox common stock were withheld by the company at $108.73 per share to satisfy tax obligations, a routine non-market transaction.
After this withholding, Hyder directly holds 34,969 shares of Clorox common stock, which the disclosure notes includes 10 shares acquired through a dividend reinvestment feature of the company’s stock incentive plan.
Clorox executive Stacey Grier reported a small, routine share disposition tied to taxes rather than a market trade. On vesting of restricted stock, the company withheld 32 shares of common stock at a value of $108.73 per share to cover tax obligations.
After this tax-withholding disposition, Grier directly holds 32,116 Clorox shares. This total includes 10 shares acquired through a dividend reinvestment feature of the company’s stock incentive plan, indicating the filing reflects compensation and administrative activity rather than an open-market sale.
The Clorox Company director reports new deferred stock units tied to CLX common stock. A Form 4 filing shows acquisitions of derivative securities classified as deferred stock units on several 2025 dates. These units convert into Clorox common stock on a 1-for-1 basis.
The director acquired 227.0333 deferred stock units on 11/06/2025 and additional amounts of 1,637.8577 and 272.7363 deferred stock units on 12/31/2025, all at a price of $0.0000 per unit. Following these transactions, the director directly beneficially owns 21,596.5756 deferred stock units.
The filing explains that some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, some represent an annual award under the 2005 Stock Incentive Plan, and others reflect electing to receive quarterly director fees in deferred stock units. These units will be settled entirely in Clorox stock when the director retires or otherwise leaves the board.
Clorox Company director equity compensation and fee deferral is reported in this insider trading disclosure. The filing shows several awards of deferred stock units, each representing the right to receive an equal number of Clorox common shares.
On 11/06/2025, the director acquired 179.1424 deferred stock units at an exercise price of $0.0000, bringing the balance to 15,533.383 units held directly. On 12/31/2025, the director acquired an additional 1,637.8577 deferred stock units and a further 334.7218 units, increasing direct holdings to about 17,505.9625 deferred stock units.
The disclosure notes that some units were obtained through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, others as the annual deferred stock unit award under the 2005 Stock Incentive Plan, and others received instead of quarterly director cash fees. The units will be settled 100% in Clorox stock upon the director’s retirement or other termination of board service.
The Clorox Company director reports additional deferred stock units related to board compensation and dividend reinvestment. On November 6, 2025, the director acquired 199.1684 deferred stock units, each convertible into one share of Clorox common stock, at a price of $0.0000 per unit, bringing the total beneficially owned to 17,269.8302 units.
On December 31, 2025, the director received an additional 1,637.8577 deferred stock units as an annual award and 520.6784 deferred stock units in lieu of quarterly director fees, increasing total holdings to 19,428.3663 deferred stock units. These units are credited under Clorox’s independent director compensation plans and will be settled in Clorox stock when the director retires or otherwise leaves the board.
The Clorox Company director reported several deferred stock unit transactions. On 11/06/2025, the director acquired 63.1574 deferred stock units through dividend reinvestment under the Independent Directors' Deferred Compensation Plan on a 1-for-1 basis with Clorox common stock. On 12/31/2025, the director received 1,637.8577 deferred stock units as an annual award under the 2005 Stock Incentive Plan, and 272.7363 deferred stock units in lieu of quarterly director fees. All units have an exercise price of $0.0000 and each unit represents one share of Clorox common stock. Following these transactions, the director beneficially owns 7,386.9498 deferred stock units, which will be settled in Clorox stock upon retirement or other termination of service as a director.
Clorox Co. (CLX) disclosed a Form 4 for a director reporting routine deferred stock unit activity during 2025. The filing shows multiple acquisitions of deferred stock units tied to Clorox common stock, including 74.9914 units on 02/14/2025, 82.9936 on 05/09/2025, 97.043 on 08/29/2025, 109.0592 on 11/06/2025, and an annual award of 1,637.8577 units on 12/31/2025, all at a price of $0.0000.
After these transactions, the director beneficially owns 11,094.3468 deferred stock units directly. The units are credited on a 1-for-1 basis and will be settled 100% in Clorox stock in connection with the director’s retirement or other termination of service. Some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, and the year-end grant was made under the 2005 Stock Incentive Plan.
The Clorox Company director reported routine equity compensation activity in the form of deferred stock units. The filing shows several acquisitions of deferred stock units tied to Clorox common stock during 2025, including transactions dated 02/14/2025, 05/09/2025, 08/29/2025, 11/06/2025, and 12/31/2025. These awards were recorded at an exercise price of $0.0000 per unit.
The director’s beneficial holdings in these derivative securities increased to 15,677.4328 deferred stock units held directly. The explanation notes that some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, while an additional annual award was granted under the 2005 Stock Incentive Plan. Each deferred stock unit represents a 1-for-1 right to receive Clorox stock, to be settled in shares upon the director’s retirement or other termination of service from the board.
The Clorox Company director reports routine deferred stock awards. A board member of Clorox (ticker CLX) reported several grants of deferred stock units that each convert 1-for-1 into Clorox common stock. On 11/06/2025, the director acquired 219.3396 deferred stock units, bringing the beneficial holding to 19,018.8638 units. On 12/31/2025, additional awards of 1,219.1572 and 145.2617 deferred stock units increased the total to 20,383.2827 units held directly.
The filing explains that some units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, some represent the annual deferred stock unit award under the 2005 Stock Incentive Plan, and some reflect stock units received instead of a portion of quarterly director fees. All deferred stock units will be settled entirely in Clorox stock when the director retires or otherwise leaves the board.
Clorox Co. director deferred stock unit grants and reinvestments
A director of Clorox Co. reported multiple acquisitions of deferred stock units tied to Clorox common stock during 2025. On several dates, including 02/14/2025, 05/09/2025, 08/29/2025, and 11/06/2025, small fractional amounts of deferred stock units were acquired through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, each at an exercise price of $0.0000 and on a 1-for-1 basis into Clorox stock.
On 12/31/2025, the director received an additional 1,637.8577 deferred stock units as an annual award under the 2005 Stock Incentive Plan, also with a conversion price of $0.0000. Following these transactions, the director beneficially owned a total of 4,471.9997 deferred stock units, which will be settled 100% in Clorox stock upon retirement or other termination of service as a director.
Clorox Co. director reported routine equity-based compensation and fee deferrals in the form of deferred stock units. On 11/06/2025, the director acquired 8.9351 deferred stock units tied to Clorox common stock through dividend reinvestment under the Independent Directors' Deferred Compensation Plan, bringing the beneficially owned balance to 774.7598 units.
On 12/31/2025, the director received an annual award of 1,637.8577 deferred stock units under the 2005 Stock Incentive Plan, increasing holdings to 2,412.6175 units, and an additional 334.7218 deferred stock units in lieu of cash quarterly director fees, for a new total of 2,747.3393 units. All deferred stock units are scheduled to be settled 100% in Clorox stock after the director retires or otherwise leaves the board.
The Clorox Company reported a routine equity grant to a director. On 12/31/2025, the director received an annual award of 1-for-1 Deferred Stock Units under the company’s 2005 Stock Incentive Plan. The transaction, reported on a Form 4 for one reporting person, shows 1,637.8577 Deferred Stock Units credited at a price of $0.0000 per unit.
The Deferred Stock Units are tied to Clorox common stock and will be settled 100% in Clorox shares in connection with the director’s retirement or other termination of board service. The filing characterizes this as an annual award, reflecting ongoing non-cash compensation for board service rather than an open-market purchase or sale.
The Clorox Company director reports a routine stock-based compensation grant. A board member received an annual award of 825.0862 Deferred Stock Units on 12/31/2025 under the company’s 2005 Stock Incentive Plan. Each unit is described as a 1-for-1 right tied to a share of Clorox common stock, with a stated price of $0.0000 per unit, indicating this is a compensation award rather than an open‑market purchase. The filing states these Deferred Stock Units will be settled entirely in Clorox stock when the director retires or otherwise leaves the board, so the director’s economic interest in the company increases but actual shares will be issued in the future.
Clorox Co (CLX) reported an insider equity transaction by its EVP and Chief Operating Officer. On 12/12/2025, the executive had 255 shares of Clorox common stock withheld at $102.83 per share in a transaction coded F, which the company explains was to satisfy employment tax obligations tied to previously granted restricted stock units for a retirement-eligible employee. Following this withholding, the executive directly beneficially owns 69,058 shares of Clorox common stock.
Clorox Company reported that its Chief Executive Officer and director had 829 shares of common stock withheld on December 12, 2025 at a price of $102.83 per share. According to the explanation, the company withheld these shares to satisfy employment tax obligations applicable to restricted stock units previously granted to retirement eligible employees. After this tax-related share withholding, the executive directly beneficially owns 201,161 shares of Clorox common stock.
Clorox Company executive reports a small share withholding for taxes. A vice president who serves as CAO and corporate controller reported that on 12/12/2025 the company withheld 24 shares of common stock at $102.83 per share. This withholding was used to satisfy employment tax obligations tied to previously granted restricted stock units for retirement-eligible employees.
After this transaction, the officer beneficially owns 6,968 Clorox shares directly and 100 shares indirectly through a trust of a parent, indicating the filing reflects routine tax-related share withholding rather than an open-market sale.
Clorox Company reported that its EVP - Chief Admin Officer had 310 shares of common stock withheld on 12/12/2025 to cover employment tax obligations tied to previously granted restricted stock units. The shares were valued at $102.83 each for this tax-related withholding. Following this routine transaction, the officer directly beneficially owns 37,970 shares of Clorox common stock.
The Clorox Company executive reported a routine tax-related share withholding. On 12/12/2025, the EVP–Group President, Health & Hygiene had 133 shares of Clorox common stock disposed of at $102.83 per share in a transaction coded "F," which denotes shares applied to obligations such as taxes. According to the explanation, the Company withheld these shares to satisfy employment tax obligations tied to restricted stock units previously granted to "retirement eligible employees." After this transaction, the executive directly beneficially owned 35,000 shares of Clorox common stock.
Clorox Co. reported a small insider share disposition by an executive officer who serves as EVP - Executive Chief of Staff. On 12/12/2025, 65 shares of Clorox common stock were disposed of at $102.83 per share in a transaction coded “F,” reflecting shares withheld by the company to cover employment tax obligations on previously granted restricted stock units to a retirement-eligible employee.
After this tax-related withholding, the executive beneficially owns 32,138 shares of Clorox common stock in direct ownership.
Clorox Co. reported an insider share transaction by its EVP - Chief Legal Officer. On 12/12/2025, 347 shares of common stock were withheld at $102.83 per share. This was described as a company withholding of shares to satisfy employment tax obligations on previously granted restricted stock units for a retirement-eligible employee.
After this tax-related transaction, the executive beneficially owns 29,787 shares of Clorox common stock directly and 619.721 shares indirectly through a 401(k) plan. The filing is an ownership update rather than an open-market purchase or sale.
Clorox Co. (CLX) reported an insider equity transaction by a director. On 11/21/2025, a trust associated with the director acquired 4,000 shares of Clorox common stock at a weighted average price of $104.1291 per share, as shown in Table I.
Following this transaction, the trust beneficially owned 13,000 Clorox shares, reported as indirect ownership. The filing notes that the 4,000-share trade was executed in multiple transactions at prices ranging from $104.00 to $104.24, with the single price reported reflecting the weighted average of those trades.
Insider transaction summary for CLOROX CO (CLX)
On 10/03/2025 Director and Chief Executive Officer Linda J. Rendle received 43,370 shares of common stock following settlement of a 2022 performance unit grant that vested on 10/03/2025. The shares were issued at an effective price of $122.25 per share. The filing shows share withholding to satisfy tax obligations: 1,022 shares withheld for performance stock unit taxes and 8,440 shares withheld for restricted stock taxes. After these transactions and including 4,274 dividend-reinvested shares, the reporting person beneficially owned 201,990 shares (direct).
Laurene E. Peck, Vice President, Chief Accounting Officer & Corporate Controller of Clorox Co (CLX), reported changes in her beneficial ownership on 10/03/2025. She received 1,418 shares on settlement of a 2022 performance unit grant at a reported price of $122.25 per share and elected to defer settlement under the 2005 Stock Incentive Plan. The filing shows share withholding to cover tax obligations: 36 shares withheld for performance stock units and 243 shares withheld for restricted stock, both at $122.25. Following these transactions and including a 186-share dividend reinvestment, total beneficial ownership is reported as 7,271 shares (direct) before certain adjustments and 6,992 shares noted as indirect via a trust of a parent. The form is signed by an attorney-in-fact on 10/07/2025.
Insider stock settlement and tax withholdings recorded for CLOROX (CLX). On 10/03/2025 the reporting person received 6,812 common shares at $122.25 as the settlement of a 2022 performance unit award that vested and was elected for deferral under the company plan. The company withheld 162 shares and 948 shares to satisfy tax obligations for performance stock units and restricted stock, respectively. After these transactions the reported beneficial ownership declined to 35,133 shares, which includes 722 shares from dividend reinvestment.
Clorox Co. executive Stacey Grier reported receiving 9,913 shares of common stock on October 3, 2025, in settlement of a 2022 Performance Unit Grant valued at $122.25 per share, with part of the award deferred under the company’s Stock Incentive Plan. On the same date, 1,032 shares were withheld by the company to satisfy tax obligations related to vesting awards. After these transactions, Grier directly owns 32,203 shares of Clorox common stock, including 1,004 acquired through the plan’s dividend reinvestment feature.
Executive stock vesting and tax-related share withholdings: The Chief Operating Officer reported transactions on 10/03/2025 involving 15,489 shares issued upon settlement of a 2022 performance unit grant at an indicated price of $122.25 per share. The filing shows the company withheld 2,755 shares to satisfy tax obligations for restricted stock and 7,436 shares to satisfy tax obligations for performance stock units. After these transactions the reporting person beneficially owned 69,313 shares (including 739 dividend-reinvested shares).
Insider transaction summary: An executive officer of Clorox Co. (CLX) reported transactions on 10/03/2025 that settled a 2022 performance-unit grant into 9,293 shares of common stock at a per-share price of $122.25. The filing shows two share withholdings to satisfy tax obligations: 1,653 shares and 3,488 shares, each recorded at $122.25. Following these transactions the reporting person beneficially owns 38,280 shares (this total includes 534 shares from dividend reinvestment). The Form 4 was signed by an attorney-in-fact on 10/07/2025.
Insider transactions at Clorox Co (CLX): an executive reported multiple equity transactions on 10/03/2025. The reporting person acquired 8,672 shares through settlement of a 2022 performance unit grant at an effective price of $122.25, increasing direct holdings to 35,667 shares. The filing also shows withholding of 1,904 and 3,629 shares to satisfy tax obligations tied to restricted stock and performance stock units, respectively, and 462 shares from dividend reinvestment. Additionally, 612.574 shares are held indirectly via the company 401(k). The form was signed by an attorney-in-fact on 10/07/2025.
Clorox insider transaction: The company's EVP & Chief Financial Officer received 2,581 shares upon settlement of a 2022 Performance Unit Grant that vested on 10/03/2025 at a reported per-share value of $122.25. The filing shows two share-withholdings to satisfy tax obligations: 421 shares withheld for restricted stock taxes and 893 shares withheld for performance stock unit taxes. After these transactions, the reporting person beneficially owned 20,864 shares (which includes 167 dividend-reinvestment shares).
Nina Barton, EVP-Group Pres–Care & Conn at Clorox Co. (CLX), reported a sale of 622 shares of Clorox common stock on 10/03/2025 at a price of $122.25 per share. The transaction is recorded as code F and is explained as withholding of shares to satisfy tax obligations related to the vesting of restricted stock. After the transaction, Ms. Barton beneficially owns 27,895 shares, which includes 21 shares acquired via a dividend reinvestment feature of the Company’s Stock Incentive Plan.
The report was signed by an attorney-in-fact on 10/07/2025. The filing indicates a routine tax-withholding disposition rather than an open-market sale, and it shows continued significant insider ownership by an executive responsible for the company’s care and consumer connections businesses.
Christopher J. Williams, a director of Clorox Co. (CLX), reported two grants of Deferred Stock Units (DSUs) on a Form 4. On 08/29/2025 he received 199.8083 DSUs through dividend reinvestment; on 09/30/2025 he received 212.8954 DSUs in lieu of quarterly director fees. The DSUs are 1-for-1 and will be settled in Clorox common stock upon the reporting person’s retirement or other termination of director service. Following these transactions, the reporting person beneficially owns 19,458.9483 shares (reported as 19,246.0529 before the 09/30/2025 grant).
Russell J. Weiner, a director of Clorox Co. (CLX), received additional deferred stock units (DSUs) under the company's Independent Directors' Deferred Compensation Plan. On 08/29/2025 he was credited with 156.7731 DSUs via dividend reinvestment and on 09/30/2025 he received 253.4469 DSUs in lieu of quarterly director fees. The reported DSUs will be settled 100% in Clorox common stock when the reporting person retires or otherwise terminates service as a director. After these transactions the reporting person beneficially owned 15,354.2406 DSUs (expressed as common stock equivalents) held directly.